RheoSwitch Therapeutic System gene switch (RTS)

The **RheoSwitch Therapeutic System gene switch** (RTS) is a clinically validated, synthetic, ligand-inducible gene regulation platform designed for tight, reversible, and dose-dependent control of therapeutic transgene expression in gene therapy. The system utilizes two engineered fusion proteins derived from the ecdysone receptor (from insects) and other modular transcriptional domains, which remain inactive until a small-molecule ligand (such as veledimex) is administered. Upon ligand binding, the proteins heterodimerize, bind to an inducible promoter, and activate transcription only as long as the ligand is present, allowing precise external regulation of the introduced therapeutic gene. RTS has been used in clinical and preclinical studies to control intratumoral or in vivo expression of immunoregulatory cytokines such as interleukin-12 (IL-12) in cancer, and is being explored as a safety-optimized gene therapy system in other disease contexts[2][4][5][6][7]. The RheoSwitch gene switch itself is not a receptor, enzyme, endogenous human protein, or traditional drug target, but an engineered gene circuit for regulated gene therapy. **Notes:** - **is_target** is false because the RTS is **not** a classical biomolecular therapeutic target (e.g., not a receptor, enzyme, transporter, etc.): rather, it is a synthetic gene regulation system. - **is_incorrect** is true: the RTS gene switch is not a biological molecule but a regulated expression platform/system, not a therapeutic target per standard drug discovery usage. - RTS-regulated gene therapies may target canonical molecules (e.g., IL-12, gene of interest), but the gene switch system itself is a delivery/regulation tool, not a direct pharmacological target.

Other names

RheoSwitch Therapeutic SystemRTSRTS gene switch

The RTS gene switch consists of two constitutively-expressed fusion proteins: Gal4-EcR and VP16-RXR (variants exist). In the absence of the activator ligand (veledimex or INXN-1001), the system remains off and prevents transgene expression. Upon oral administration of the ligand, the two fusion proteins heterodimerize, bind to an inducible promoter, and activate transcription of the therapeutic gene of interest